Clinical trial Recruiting at 57 sites Phase 3 Interventional Ages 18 and up

Keeping fibromyalgia symptoms controlled with AXS-14 (esreboxetine) after an initial response

Official title: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia

Run by Axsome Therapeutics, Inc. · NCT07398417 · Data updated 2026-11-12

This Phase 3 study will try AXS-14 (esreboxetine) in adults with fibromyalgia who respond to initial open treatment to see if continuing the drug keeps symptoms controlled better than switching to placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment620 (estimated)
SponsorAxsome Therapeutics, Inc.
Industry-sponsored
Locations57 sites (Glendale, Arizona and 56 other locations)
StatusRecruiting
StartedJanuary 14, 2026
Main results expectedMarch 2028
Study endsMarch 2028
Registry record updatedNovember 10, 2026
Trial IDNCT07398417 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with a primary diagnosis of fibromyalgia by 2016 ACR criteria who can provide informed consent, comply with study procedures, and are not currently receiving reboxetine/esreboxetine are ideal candidates.

Probably not a fit

Patients who do not respond during the open-label period, those with prior exposure to reboxetine/esreboxetine, or those judged medically inappropriate by investigators are unlikely to benefit from the randomized withdrawal phase.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, multicenter trial uses a randomized withdrawal design to test whether continued AXS-14 maintains symptom control in adults with fibromyalgia. All participants receive open-label AXS-14 for 12 weeks, and those who meet response criteria are randomized 1:1 to continue AXS-14 or switch to placebo for up to 12 weeks under double-blind conditions. Participants are followed until loss of therapeutic response or the end of the double-blind period, with efficacy and safety monitored throughout. The design enriches the randomized cohort with initial responders to directly measure durability of effect.

Why it matters

Potential benefit: If successful, continuing AXS-14 could prolong symptom relief and reduce recurrence of fibromyalgia symptoms in patients who initially respond.

How similar studies have gone: Randomized withdrawal designs are commonly used to test maintenance of benefit, and prior trials of norepinephrine reuptake inhibitors in fibromyalgia have shown mixed results rather than consistent success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Has a primary diagnosis of fibromyalgia based on the 2016 ACR diagnostic criteria.
* Male or female, ≥18 years of age.
* Provides written informed consent to participate in the study before conducting any study procedures.

Exclusion Criteria:

* Previous participation in a clinical trial with reboxetine or esreboxetine or currently receiving treatment with reboxetine for any condition.
* Unable to comply with study procedures.
* Medically inappropriate for study participation in the opinion of the investigator.

Where it's running

  • Clinical Research Site
    Glendale, Arizona, United States
    Recruiting
  • Clinical Research Site
    Phoenix, Arizona, United States
    Recruiting
  • Clinical Research Site
    Tucson, Arizona, United States
    Recruiting
  • Clinical Research Site
    Little Rock, Arkansas, United States
    Recruiting
  • Clinical Research Site
    Anaheim, California, United States
    Recruiting
  • Clinical Research Site
    Oceanside, California, United States
    Recruiting
Show 44 more locations
  • Clinical Research Site
    Redlands, California, United States
    Recruiting
  • Clinical Research Site
    Sacramento, California, United States
    Recruiting
  • Clinical Research Site
    Santa Ana, California, United States
    Recruiting
  • Clinical Research Site
    Cromwell, Connecticut, United States
    Recruiting
  • Clinical Research Site
    Hollywood, Florida, United States
    Recruiting
  • Clinical Research Site
    Jacksonville, Florida, United States
    Recruiting
  • Clinical Research Site
    Lakeland, Florida, United States
    Recruiting
  • Clinical Research Site
    Maitland, Florida, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida, United States
    Recruiting
  • Clinical Research Site
    Orlando, Florida, United States
    Recruiting
  • Clinical Research Site
    Tampa, Florida, United States
    Recruiting
  • Clinical Research Site
    The Villages, Florida, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Clinical Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Clinical Research Site
    Marietta, Georgia, United States
    Recruiting
  • Clinical Research Site
    Norcross, Georgia, United States
    Recruiting
  • Clinical Research Site
    Chicago, Illinois, United States
    Recruiting
  • Clinical Research Site
    Tinley Park, Illinois, United States
    Recruiting
  • Clinical Research Site
    Kansas City, Kansas, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas, United States
    Recruiting
  • Clinical Research Site
    Overland Park, Kansas, United States
    Recruiting
  • Clinical Research Site
    Louisville, Kentucky, United States
    Recruiting
  • Clinical Research Site
    Prairieville, Louisiana, United States
    Recruiting
  • Clinical Research Site
    Rockville, Maryland, United States
    Recruiting
  • Clinical Research Site
    Boston, Massachusetts, United States
    Recruiting
  • Clinical Research Site
    North Dartmouth, Massachusetts, United States
    Recruiting
  • Clinical Research Site
    Watertown, Massachusetts, United States
    Recruiting
  • Clinical Research Site
    Hazelwood, Missouri, United States
    Recruiting
  • Clinical Research Site
    Springfield, Missouri, United States
    Recruiting
  • Clinical Research Site
    Town and Country, Missouri, United States
    Recruiting
  • Clinical Research Site
    Las Vegas, Nevada, United States
    Recruiting
  • Clinical Research Site
    Brooklyn, New York, United States
    Recruiting
  • Clinical Research Site
    Hartsdale, New York, United States
    Recruiting
  • Clinical Research Site
    Williamsville, New York, United States
    Recruiting
  • Clinical Research Site
    High Point, North Carolina, United States
    Recruiting
  • Clinical Research Site
    Huber Heights, Ohio, United States
    Recruiting
  • Clinical Research Site
    Milford, Ohio, United States
    Recruiting
  • Clinical Research Site
    Tulsa, Oklahoma, United States
    Recruiting
  • Clinical Research Site
    Duncansville, Pennsylvania, United States
    Recruiting
  • Clinical Research Site
    Plymouth Meeting, Pennsylvania, United States
    Recruiting
  • Clinical Research Site
    Cranston, Rhode Island, United States
    Recruiting
  • Clinical Research Site
    Charleston, South Carolina, United States
    Recruiting
  • Clinical Research Site
    Knoxville, Tennessee, United States
    Recruiting
  • Clinical Research Site
    Memphis, Tennessee, United States
    Recruiting

+7 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.